GSK (NYSE:GSK) is reportedly suing Pfizer (PFE) and partner BioNTech (BNTX) for patent infringement over the use of certain mRNA technology for their COVID-19 Comirnaty vaccines. GSK, also known as ...
A trio of drugmakers are treading the boards to raise awareness of global antimicrobial resistance (AMR). | A trio of ...
“Defendants have repeatedly touted the speed at which they produced their original COVID-19 vaccine and were later able to modify it to address new viral strains but have consistently failed to ...
DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an ...
LONDON (AP) — The pharmaceutical giant GlaxoSmithKline said Saturday it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit, a joint ...
GlaxoSmithKline hasn’t made plans to pursue an initial public offering on the consumer health company it created with Pfizer, a top executive told Bloomberg a day after Pfizer’s CEO said they plan to ...
Zacks Investment Research on MSN
GSK stock up almost 19% in 3 months: Should you buy, hold or sell?
GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...
* Will target one of biggest killers of children * Could save millions of lives * Glaxo, Pfizer each to supply 30 mln doses/year for 10 yrs * Firms will get $7/dose for first 20 pct, then $3.50/dose * ...
LONDON (Reuters) - GlaxoSmithKline and Pfizer , two leading developers of AIDS drugs, are merging their HIV operations into a new company that will hold nearly a fifth of the market for treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback